PF PRISM CV Company Profile

What is the competitive landscape for PF PRISM CV, and when can generic versions of PF PRISM CV drugs launch?

PF PRISM CV has sixteen approved drugs.

There are twenty-nine US patents protecting PF PRISM CV drugs.

There are six hundred and fifteen patent family members on PF PRISM CV drugs in sixty-six countries and seventy-two supplementary protection certificates in eighteen countries.

Summary for PF PRISM CV

International Patents:	615
US Patents:	29
Tradenames:	11
Ingredients:	11
NDAs:	16

Drugs and US Patents for PF PRISM CV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-003	Aug 20, 2014	AB	RX	Yes	No	8,269,040			Y
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-001	Sep 4, 2012		RX	Yes	Yes	7,767,678*PED				Y
Pf Prism Cv	TYGACIL	tigecycline	POWDER;INTRAVENOUS	021821-001	Jun 15, 2005	AP	RX	Yes	Yes	10,588,975		Y
Pf Prism Cv	BOSULIF	bosutinib monohydrate	TABLET;ORAL	203341-003	Oct 27, 2017		RX	Yes	No
Pf Prism Cv	CHANTIX	varenicline tartrate	TABLET;ORAL	021928-001	May 10, 2006		DISCN	Yes	No

Expired US Patents for PF PRISM CV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-001	Aug 25, 2000	5,145,684*PED
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-001	Aug 25, 2000	5,308,847*PED
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002	5,100,899*PED
Pf Prism Cv	VFEND	voriconazole	INJECTABLE;INTRAVENOUS	021267-001	May 24, 2002	5,376,645
Pf Prism Cv	PRISTIQ	desvenlafaxine succinate	TABLET, EXTENDED RELEASE;ORAL	021992-001	Feb 29, 2008	7,291,347

Paragraph IV (Patent) Challenges for PF PRISM CV drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	50 mg and 100 mg		2012-02-29
	Tablets	0.5 mg and 1 mg		2010-05-10
	Tablets	5 mg		2016-11-07
	Tablets	100mg and 500mg		2016-09-06
	For Injection	200 mg/vial		2008-09-12
	Oral Suspension	40 mg/mL		2010-10-08
	Injection	25 mg/mL, 1.8 mL vial		2011-05-25
	Tablets	0.5 mg		2010-08-25
	Extended-release Tablets	25 mg		2015-05-08
	Tablets	1 mg and 5 mg		2018-02-23
	Tablets	400 mg		2018-10-15
	Tablets	50 mg and 200 mg		2008-04-14
	For Injection	50 mg per vial		2009-06-15
	Tablets	1 mg and 2 mg		2009-12-17

International Patents for PF PRISM CV Drugs

Country	Patent Number	Estimated Expiration
New Zealand	535464
Australia	2016280003
Algeria	3248
South Korea	20080074950
Taiwan	200518784

Supplementary Protection Certificates for PF PRISM CV Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1218348	13C0010	France		PRODUCT NAME: AXITINIB, ET OPTIONNELLEMENT SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/777/001 20120903
1786785	449	Finland
0648494	01C0037	France		PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001-005 20010313; FIRST REGISTRATION: IKS55243 20000926
1218348	C 2013 006	Romania		PRODUCT NAME: AXITINIB,OPTIONAL SUB FORMA DE SARE ACCEPTABILA FARMACEUTIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/12/777/001, RO EU/1/12/777/002, RO EU/1/12/777/003, RO EU/1/12/777/004, RO EU/1/12/777/005, RO EU/1/12/777/006; DATE OF NATIONAL AUTHORISATION: 20120903; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/12/777/001, EMEA EU/1/12/777/002, EMEA EU/1/12/777/003, EMEA EU/1/12/777/004, EMEA EU/1/12/777/005, EMEA EU/1/12/777/006; DATE OF FIRST AUTHORISATION IN EEA: 20120903
1218348	122013000016	Germany		PRODUCT NAME: AXITINIB, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/12/777/001-006 20120903

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pf Prism Cv